{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:15:01Z","timestamp":1785888901502,"version":"3.56.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":38,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.berh.2026.102139","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T03:40:26Z","timestamp":1775187626000},"page":"102139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cellular therapies in systemic Sclerosis: immunopathogenesis-informed precision targeting with CAR-T and CAR-NK approaches"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4644-0558","authenticated-orcid":false,"given":"Gerard","family":"Convey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Nikpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2026.102139_bib1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jaad.2021.10.065","article-title":"Systemic sclerosis in adults. Part I: clinical features and pathogenesis","volume":"87","author":"Jerjen","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2026.102139_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00281-025-01065-6","article-title":"Systemic sclerosis: pathogenic mechanisms and their implications for treatment","volume":"47","author":"Lescoat","year":"2025","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.berh.2026.102139_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1551911","article-title":"A review of recent studies on the pathogenesis of systemic sclerosis: focus on fibrosis pathways","volume":"16","author":"Jimenez","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib4","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1093\/rheumatology\/keab190","article-title":"Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis","volume":"60","author":"Bairkdar","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2026.102139_bib5","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/rheumatology\/kez486","article-title":"Racial differences in systemic sclerosis disease presentation: a European Scleroderma trials and research group study","volume":"59","author":"Jaeger","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2026.102139_bib6","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/art.22910","article-title":"Depression in patients with systemic sclerosis: a systematic review of the evidence","volume":"57","author":"Thombs","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2026.102139_bib7","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2026.102139_bib8","first-page":"CD008506","article-title":"Stem cell transplantation for systemic sclerosis","author":"Bruera","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2026.102139_bib9","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/BOR.0000000000001063","article-title":"A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018-2024","volume":"37","author":"Good","year":"2025","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2026.102139_bib10","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s12016-021-08889-8","article-title":"Current concepts on the pathogenesis of systemic sclerosis","volume":"64","author":"Truchetet","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814287","article-title":"The pathogenesis of systemic sclerosis: the origin of fibrosis and interlink with vasculopathy and autoimmunity","volume":"24","author":"Ko","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.berh.2026.102139_bib12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/annrheumdis-2016-210229","article-title":"Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis","volume":"76","author":"Manetti","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102139_bib13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41467-023-44645-6","article-title":"Systems-based identification of the Hippo pathway for promoting fibrotic mesenchymal differentiation in systemic sclerosis","volume":"15","author":"Ma","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.berh.2026.102139_bib14","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","article-title":"The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis","volume":"75","author":"Brkic","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102139_bib15","article-title":"M2 macrophage polarization in systemic sclerosis fibrosis: pathogenic mechanisms and therapeutic effects","volume":"9","author":"Hu","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.berh.2026.102139_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103637","article-title":"The intervention of macrophages in progressive fibrosis characterizing systemic sclerosis: a systematic review","volume":"23","author":"Campitiello","year":"2024","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102139_bib17","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.jid.2024.03.031","article-title":"Neutrophil-driven M2-like macrophages are critical for skin fibrosis in a systemic sclerosis model","volume":"144","author":"Gong","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.berh.2026.102139_bib18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/cei.13426","article-title":"Toll-like receptors in mediating pathogenesis in systemic sclerosis","volume":"201","author":"Frasca","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib19","doi-asserted-by":"crossref","first-page":"eaam8458","DOI":"10.1126\/scitranslmed.aam8458","article-title":"Plasmacytoid dendritic cells promote systemic sclerosis with a key role for TLR8","volume":"10","author":"Ah Kioon","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.berh.2026.102139_bib20","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20231809","article-title":"Altered X-chromosome inactivation of the TLR7\/8 locus and heterogeneity of pDCs in systemic sclerosis","volume":"222","author":"Du","year":"2025","journal-title":"J Exp Med"},{"key":"10.1016\/j.berh.2026.102139_bib21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/ijms24010653","article-title":"CXCL4-RNA complexes circulate in systemic sclerosis and amplify inflammatory\/pro-fibrotic responses by myeloid dendritic cells","volume":"24","author":"Pietraforte","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.berh.2026.102139_bib22","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1093\/rheumatology\/keab532","article-title":"Hypoxia and TLR9 activation drive CXCL4 production in systemic sclerosis plasmacytoid dendritic cells via mtROS and HIF-2\u03b1","volume":"61","author":"Ottria","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2026.102139_bib23","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10067-003-0706-5","article-title":"The roles of transforming growth factor type beta3 (TGF-beta3) and mast cells in the pathogenesis of scleroderma","volume":"22","author":"Ozbilgin","year":"2003","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2026.102139_bib24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1136\/annrheumdis-2015-207388","article-title":"Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis","volume":"75","author":"Wohlfahrt","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102139_bib25","article-title":"Natural killer cells are decreased in systemic sclerosis and have diagnostic value for pulmonary arterial hypertension incorporation","volume":"15","author":"Guo","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.berh.2026.102139_bib26","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3389\/fimmu.2018.01665","article-title":"Natural killer cells exhibit a peculiar phenotypic profile in systemic sclerosis and are potent inducers of endothelial microparticles release","volume":"9","author":"Benyamine","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102574","article-title":"Longitudinal analysis of T-cell receptor repertoires reveals persistence of antigen-driven CD4 and CD8 T-cell clusters in systemic sclerosis","volume":"117","author":"Servaas","year":"2021","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.berh.2026.102139_bib28","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/j.1365-2133.2009.09213.x","article-title":"Clonal T-Cell populations are frequent in the skin and blood of patients with systemic sclerosis","volume":"161","author":"Kreuter","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2026.102139_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.154799","article-title":"Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis","volume":"125","author":"Gasparini","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.berh.2026.102139_bib30","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/BOR.0000000000000553","article-title":"T cells and cytokines in systemic sclerosis","volume":"30","author":"Fuschiotti","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2026.102139_bib31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biopha.2018.09.037","article-title":"Imbalance between T helper 17 and regulatory T cell subsets plays a significant role in the pathogenesis of systemic sclerosis","volume":"108","author":"Mo","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.berh.2026.102139_bib32","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1093\/rheumatology\/keae190","article-title":"Systemic sclerosis-associated pulmonary arterial hypertension is characterized by a distinct peripheral T helper cell profile","volume":"63","author":"Papadimitriou","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2026.102139_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.900638","article-title":"The pathophysiological roles of regulatory T cells in the early phase of systemic sclerosis","volume":"13","author":"Kobayashi","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib34","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jaci.2014.12.1932","article-title":"Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis","volume":"135","author":"MacDonald","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.coi.2010.08.004","article-title":"Developmental plasticity of Foxp3+ regulatory T cells","volume":"22","author":"Hori","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib36","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000450949","article-title":"Disease manifestation and inflammatory activity as modulators of Th17\/Treg balance and RORC\/FoxP3 methylation in systemic sclerosis","volume":"171","author":"Almanzar","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib37","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1093\/rheumatology\/keac489","article-title":"Dendritic cells drive profibrotic inflammation and aberrant T cell polarization in systemic sclerosis","volume":"62","author":"Chore\u00f1o-Parra","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2026.102139_bib38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13075-020-02383-w","article-title":"Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis","volume":"23","author":"Fox","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102139_bib39","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1172\/JCI131700","article-title":"Cytotoxic CD4+ T lymphocytes May induce endothelial cell apoptosis in systemic sclerosis","volume":"130","author":"Maehara","year":"2020","journal-title":"J Clin Investig"},{"key":"10.1016\/j.berh.2026.102139_bib40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/annrheumdis-2018-214382","article-title":"Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib","volume":"78","author":"Ricard","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102139_bib41","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2026.102139_bib42","doi-asserted-by":"crossref","first-page":"i184","DOI":"10.1093\/rheumatology\/keaf006","article-title":"Tocilizumab and rituximab for systemic sclerosis interstitial lung disease: a real-world cohort analysis","volume":"64","author":"Goldman","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2026.102139_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.938785","article-title":"Involvement of B cells in the development of systemic sclerosis","volume":"13","author":"Yoshizaki","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib44","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/art.39437","article-title":"Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis","volume":"68","author":"Mavropoulos","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102139_bib45","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/art.41927","article-title":"Defective early B cell tolerance checkpoints in patients with systemic sclerosis allow the production of self antigen-specific clones","volume":"74","author":"Glauzy","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102139_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.930970","article-title":"Can antinuclear antibodies have a pathogenic role in systemic sclerosis?","volume":"13","author":"Chepy","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib47","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/rheumatology\/keaa669","article-title":"Imbalance toward TFH 1 cells playing a role in aberrant B cell differentiation in systemic sclerosis","volume":"60","author":"Ly","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2026.102139_bib48","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.imlet.2018.01.002","article-title":"Pathogenic roles of B lymphocytes in systemic sclerosis","volume":"195","author":"Yoshizaki","year":"2018","journal-title":"Immunol Lett"},{"key":"10.1016\/j.berh.2026.102139_bib49","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/art.40016","article-title":"Scleroderma peripheral B lymphocytes secrete interleukin-6 and transforming growth factor \u03b2 and activate fibroblasts","volume":"69","author":"Dumoitier","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102139_bib50","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/1346-8138.16495","article-title":"Cytokine-producing B-cell balance associates with skin fibrosis in patients with systemic sclerosis","volume":"49","author":"Horii","year":"2022","journal-title":"J Dermatol"},{"key":"10.1016\/j.berh.2026.102139_bib51","doi-asserted-by":"crossref","first-page":"eaas9502","DOI":"10.1126\/sciadv.aas9944","article-title":"BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance","volume":"4","author":"Matsushita","year":"2018","journal-title":"Sci Adv"},{"key":"10.1016\/j.berh.2026.102139_bib52","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/jimmun\/vkaf008","article-title":"Can autoimmune disease be cured by deep CD19+ cell depletion?","volume":"214","author":"Suan","year":"2025","journal-title":"J Immunol"},{"issue":"Suppl 1","key":"10.1016\/j.berh.2026.102139_bib53","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar3908","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies","volume":"15","author":"Leandro","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2026.102139_bib54","doi-asserted-by":"crossref","first-page":"10872","DOI":"10.1038\/s41467-025-66974-4","article-title":"Autoantibody landscape and functional role of anti-C-C motif chemokine receptor 8 autoantibodies in systemic sclerosis: post-hoc analysis of a B-cell depletion trial","volume":"16","author":"Matsuda","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.berh.2026.102139_bib55","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/ar2965","article-title":"B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial","volume":"12","author":"Bosello","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102139_bib56","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamadermatol.2022.6340","article-title":"Long-term outcomes after rituximab treatment for patients with systemic sclerosis: follow-up of the DESIRES trial with a focus on serum immunoglobulin levels","volume":"159","author":"Kuzumi","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.berh.2026.102139_bib57","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","article-title":"MITIGATE trial investigators. Inebilizumab for treatment of IgG4-Related disease","volume":"392","author":"Stone","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2026.102139_bib58","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2026.102139_bib59","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/art.40656","article-title":"Baseline plasma cell gene signature predicts improvement in systemic sclerosis skin scores following treatment with inebilizumab (MEDI-551) and correlates with disease activity in systemic lupus erythematosus and chronic obstructive pulmonary disease","volume":"70","author":"Streicher","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2026.102139_bib60","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ard.2025.06.2120","article-title":"Effects of different B-cell-depleting strategies on the lymphatic tissue","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102139_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114071","article-title":"Application of blinatumomab, a bispecific anti-CD3\/CD19 T-cell engager, in treating severe systemic sclerosis: a case study","volume":"204","author":"Subklewe","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.berh.2026.102139_bib62","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"M\u00fcller","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2026.102139_bib63","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2315990121","article-title":"Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-bcma CAR-T cell therapy","volume":"121","author":"Qin","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.berh.2026.102139_bib64","first-page":"eado2084","article-title":"BCMA\/CD19 CAR T cell therapy for refractory myasthenia gravis: proteomic signatures and single-cell transcriptomics of disease flares","volume":"12","author":"Huang","year":"2026","journal-title":"Sci Adv"},{"key":"10.1016\/j.berh.2026.102139_bib65","article-title":"Increased expression of the ectoenzyme CD38 in peripheral blood plasmablasts and plasma cells of patients with systemic sclerosis","volume":"14","author":"Agarbati","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-49450-1","article-title":"Heavy-chain antibody targeting of CD38 NAD+ hydrolase ectoenzyme to prevent fibrosis in multiple organs","volume":"13","author":"Shi","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.berh.2026.102139_bib67","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.berh.2026.102139_bib68","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","article-title":"Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells","volume":"4","author":"Chmielewski","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib69","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib70","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/cells14100753","article-title":"Chimeric autoantibody receptor- and\/or peptide-MHC-based CAR therapies for targeted elimination of antigen-specific B or T cells in hypersensitivity disorders such as allergies and autoimmune diseases","volume":"14","author":"Proti\u0107-Rosi\u0107","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.berh.2026.102139_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115597","article-title":"Engineering scFv immunotherapies: from CAR T cells to bispecific antibodies","volume":"166","author":"Jamali","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.berh.2026.102139_bib72","first-page":"23","article-title":"Application of nanobody-based CAR-T in tumor immunotherapy","volume":"55","author":"Liu","year":"2025","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.berh.2026.102139_bib73","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/cells9051182","article-title":"Hinge and transmembrane domains of chimeric antigen receptor regulate receptor expression and signaling threshold","volume":"9","author":"Fujiwara","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.berh.2026.102139_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1664403","article-title":"Non-signaling but all important: how the linker, Hinge, and transmembrane domains in the CAR hold it all together","volume":"16","author":"Bernard","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib75","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.berh.2026.102139_bib76","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.berh.2026.102139_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102931","article-title":"Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases","volume":"21","author":"Su","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102139_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1461102","article-title":"CAR immunotherapy in autoimmune diseases: promises and challenges","volume":"15","author":"Yu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib79","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood.2025028375","article-title":"Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma","volume":"146","author":"M\u00fcller","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.berh.2026.102139_bib80","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ard.2025.06.301","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"84","author":"Hagen","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102139_bib81","article-title":"Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies","volume":"25","author":"Kampouri","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.berh.2026.102139_bib82","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy","volume":"30","author":"Ghilardi","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2026.102139_bib83","doi-asserted-by":"crossref","first-page":"4263","DOI":"10.1158\/1078-0432.CCR-24-1798","article-title":"Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients","volume":"30","author":"Tix","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.berh.2026.102139_bib84","article-title":"CAR-T cell manufacturing: major process parameters and next-generation strategies","volume":"221","author":"Ayala","year":"2024","journal-title":"J Exp Med"},{"key":"10.1016\/j.berh.2026.102139_bib85","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/cpt.3241","article-title":"Clinical pharmacology considerations for the \"off-the-shelf\" allogeneic cell therapies","volume":"115","author":"Mody","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 2","key":"10.1016\/j.berh.2026.102139_bib86","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1002\/sctm.21-0135","article-title":"CAR-NK cells from engineered pluripotent stem cells: off-the-shelf therapeutics for all patients","volume":"10","author":"Lu","year":"2021","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.berh.2026.102139_bib87","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.3390\/cancers14092266","article-title":"Engineering induced pluripotent stem cells for cancer immunotherapy","volume":"14","author":"Zhou","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.berh.2026.102139_bib88","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102139_bib89","first-page":"38","article-title":"CD19 CAR T-cell therapy in autoimmune disease \u2014 a case series with follow-up","volume":"30","author":"Mackensen","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2026.102139_bib90","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/annrheumdis-2024-eular.1912","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"83","author":"Auth","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2026.102139_bib91","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-04185-6","article-title":"CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1\/2 CASTLE basket trial","author":"M\u00fcller","year":"2026","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.berh.2026.102139_bib92","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-024-03451-1","article-title":"Immunological effects of CD19.CAR-T cell therapy in systemic sclerosis: an extended case study","volume":"26","author":"Claus","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2026.102139_bib93","first-page":"845","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"31","author":"Wang","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2026.102139_bib94","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1016\/j.cell.2025.05.038","article-title":"An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis","volume":"188","author":"Wang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.berh.2026.102139_bib95","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","article-title":"Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial","volume":"31","author":"Feng","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.berh.2026.102139_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103314","article-title":"Differentially expressed genes in systemic sclerosis: towards predictive medicine with new molecular tools for clinicians","volume":"22","author":"Keret","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.berh.2026.102139_bib97","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30421-5","article-title":"68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study","volume":"3","author":"Bergmann","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.berh.2026.102139_bib98","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1093\/rheumatology\/keac628","article-title":"Improving outcomes in scleroderma: recent progress of cell-based therapies","volume":"62","author":"Khanna","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2026.102139_bib99","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/1744666X.2024.2402494","article-title":"Innovative cell therapies for systemic sclerosis: available evidence and new perspectives","volume":"21","author":"Lescoat","year":"2025","journal-title":"Expet Rev Clin Immunol"},{"key":"10.1016\/j.berh.2026.102139_bib100","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","author":"Bot","year":"2025","journal-title":"Nat Rev Drug Discov"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694226000240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:26:25Z","timestamp":1785878785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694226000240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1521694226000240"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2026.102139","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cellular therapies in systemic Sclerosis: immunopathogenesis-informed precision targeting with CAR-T and CAR-NK approaches","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2026.102139","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102139"}}